VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | Phase I trial of a FcRH5-targeted BiTE in R/R myeloma

Adam Cohen, MD, Abramson Cancer Center, Philadelphia, PA, discusses the findings from a single step-up dosing cohort of an ongoing Phase I trial (NCT03275103) of cevostamab (BFCR4350A), a bispecific T-cell engager (BiTE), in patients with relapsed/refractory (R/R) multiple myeloma. Cevostamab targets FcRH5, expressed on the myeloma cell membrane, and CD3 on T-cells, inducing T-cell mediated cytotoxicity of myeloma cells. To assess the safety and initial efficacy of IV-administered cevostamab monotherapy, a dose-escalation design was used. One arm of the trial employed a single step-up dose to reduce the rate of cytokine release syndrome (CRS). The results from this cohort found that the dosing schedule effectively reduced the occurrence of severe CRS, with only one case of grade 3 CRS. cevostamab showed evidence of durable efficacy in this heavily pretreated population, with overall response rates of over 50%. Responses were consistent across patients with high-risk cytogenetics and patients with triple-class refractory disease. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.


Consulting/advisory boards: Janssen, Takeda, Celgene, BMS, Oncopeptides, GlaxoSmithKline, Astrazeneca, Genentech/Roche
Research funding: Novartis, GlaxoSmithKleine
Patent royalties: Novartis

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter